Azenta Inc (AZTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Azenta Inc stock (AZTA) is currently trading at $21.86. Azenta Inc PE ratio is 34.81. Azenta Inc PS ratio (Price-to-Sales) is 1.56. Analyst consensus price target for AZTA is $38.67. WallStSmart rates AZTA as Hold.
- AZTA PE ratio analysis and historical PE chart
- AZTA PS ratio (Price-to-Sales) history and trend
- AZTA intrinsic value — DCF, Graham Number, EPV models
- AZTA stock price prediction 2025 2026 2027 2028 2029 2030
- AZTA fair value vs current price
- AZTA insider transactions and insider buying
- Is AZTA undervalued or overvalued?
- Azenta Inc financial analysis — revenue, earnings, cash flow
- AZTA Piotroski F-Score and Altman Z-Score
- AZTA analyst price target and Smart Rating
Azenta Inc
📊 No data available
Try selecting a different time range
AZTA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Azenta Inc (AZTA)
AZTA trades 12% above its Graham fair value of $27.14, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Azenta Inc (AZTA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Azenta Inc (AZTA) Key Strengths (5)
Growing significantly faster than its price suggests
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 8778.00% year-over-year
116.05% of shares held by major funds and institutions
Paying $1.56 for every $1 of annual revenue
Supporting Valuation Data
Azenta Inc (AZTA) Areas to Watch (5)
Losing money on operations
Company is losing money with a negative profit margin
Very low returns on shareholder equity
Revenue growing slowly at 0.80% annually
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Azenta Inc (AZTA) Detailed Analysis Report
Overall Assessment
This company scores 57/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.6/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Book, EPS Growth. Valuation metrics including PEG Ratio (0.53), Price/Sales (1.56), Price/Book (0.54) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 8778.00%.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Return on Equity. Growth concerns include Revenue Growth at 0.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 1.53%, Operating Margin at -4.10%, Profit Margin at -10.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 1.53% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Book) and negatives (Operating Margin, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AZTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AZTA's Price-to-Sales ratio of 1.56x trades at a 30% premium to its historical average of 1.2x (75th percentile). The current valuation is 55% below its historical high of 3.44x set in Aug 2018, and 360% above its historical low of 0.34x in Nov 2008. Over the past 12 months, the PS ratio has compressed from ~2.1x as trailing revenue scaled faster than the stock price.
Compare AZTA with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Azenta Inc (AZTA) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Azenta Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 595M with 1% growth year-over-year. The company is currently unprofitable, posting a -10.1% profit margin.
Key Findings
Generating 15M in free cash flow and 21M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.06 indicates a conservative balance sheet with 339M in cash.
ROE of 1.5% suggests the company isn't efficiently converting equity into profits.
The company is unprofitable with a -10.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Azenta Inc.
Bottom Line
Azenta Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(7 last 3 months)
| Insider | Type | Shares |
|---|---|---|
NOVA, TINA SUSAN Director | Buy | +5,663 |
Data sourced from SEC Form 4 filings
Last updated: 10:09:51 AM
About Azenta Inc(AZTA)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Azenta Inc. is a leading provider of sample management solutions and life science tools, specializing in enhancing laboratory efficiencies for the biotechnology and pharmaceutical sectors. Leveraging innovative automated solutions, biorepository services, and advanced storage technologies, the company empowers clients to accelerate drug discovery while maintaining strict regulatory compliance. With a strong focus on cutting-edge technology and collaborative partnerships, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market. Its unwavering commitment to advancing scientific research through sophisticated products further reinforces its competitive edge in biobanking and sample management.